Bio-Path Holdings Inc
3.8517 - 3.95
2.68 - 8.62
Join Discuss about BPTH with like-minded investors
honorable mention today for intraday set up BPTH
87 Replies 7 👍 14 🔥
reminds me of KBIO LFIN DRYS BPTH etc.
142 Replies 11 👍 10 🔥
%bpth stopped on half for a NICKEL. have a good day all happy to be back on this room and seeing new smart folk
82 Replies 6 👍 13 🔥
everyone remembers bpth
66 Replies 7 👍 9 🔥
Next Dividend Date
Bio-Path is a biotechnology company developing DNAbilize®, a novel technology that has yielded a pipeline of RNAi nanoparticle drugs that can be administered with a simple intravenous infusion. Bio-Path's lead product candidate, prexigebersen (BP1001, targeting the Grb2 protein), is in a Phase 2 study for blood cancers and prexigebersen-A, a drug product modification of prexigebersen, is under consideration by the FDA to commence Phase 1 studies in solid tumors. This is followed by BP1002, targeting the Bcl-2 protein, where it is being evaluated in lymphoma clinical studies.